In Asia & Oceania, sales increased 37.1% year on year,  to ¥14.9 billion. Sales grew steadily in China. Bulk sales and royalty income from Harnal, which are  recorded under EMEA sales, declined 11.9% to  € 32 million  on a euro basis. When converted to yen, sales were up  10.4%, to ¥4.3 billion due to the impact of foreign  exchange rates. In EMEA, sales decreased 0.5%, to  € 139 million on a euro  basis. When converted to yen, sales increased 24.7%, to  ¥18.7 billion due to the impact of foreign exchange rates.  Sales were impacted mainly by price reductions, despite a  steady increase in volume due to the contribution of a  six-month formulation and other factors. In the Asia & Oceania region, this product was  launched in Hong Kong in June 2013 and in Thailand in  November 2013.  Eligard (Prostate cancer treatment) Funguard/MYCAMINE (Candin-type antifungal agent) XTANDI (prostate cancer treatment) Protopic (Treatment for atopic dermatitis) Financial Section Annual Report 2014 _  Astellas Pharma Inc.  89 In EMEA, XTANDI was launched in the United Kingdom  in July 2013, and distribution has expanded to cover 19  European countries (as of July 2014). In fiscal 2013, sales  were  € 71 million on a euro basis and ¥9.5 billion when  converted into yen. The product has made a strong start,  with sales expanding in core countries such as the U.K.,  Germany and France. Sales in Japan increased 1.0%, to ¥3.5 billion. Protopic’s  distribution rights in Japan were transferred in April 2014  to Maruho Co., Ltd., which has already been promoting  Protopic since April 2011 under an agreement with Astellas. In the Americas, sales grew by 22.3%, to US$116 mil- lion on a U.S dollar basis. When converted to yen, sales  increased by 47.5%, to ¥11.7 billion. In Asia & Oceania, sales increased 49.3%, to ¥2.6 billion. In EMEA, sales grew 21.8%, to  € 53 million on a euro  basis. When converted to yen, sales increased 52.8%, to  ¥7.1 billion. In the U.S., XTANDI was launched in September 2012  for the indication of metastatic castration-resistant prostate  cancer in patients who have previously received docetaxel  (chemotherapy). In the Americas, sales increased steadily  to US$450 million compared to US$147 million in fiscal  2012. When converted to yen, sales were ¥45.1 billion,  compared to ¥12.2 billion in fiscal 2012. In the market for  treatment of castration-resistant prostate cancer in patients  who have previous received chemotherapy, XTANDI has  steadily expanded its share of this market since launch. It  has gained a strong reputation among oncology specialists  in terms of both its efficacy and safety. In Japan, the Company obtained approval for enzalutamide  for the indication of castration-resistant prostate cancer* in  March 2014, and it was launched under the brand name  XTANDI in May 2014. Through XTANDI, the Company  intends to make new treatment options for castration- resistant prostate cancer available in Japan too. Together  with Gonax, which is already on the market, the Company  expects that XTANDI will help it to make an even greater  contribution to prostate cancer treatment. Sales in Japan decreased 4.5%, to ¥12.3 billion. Funguard’s  share in the market of injectable antifungal agents remained  high at around 53% during fiscal 2013 (on a value basis). In the Americas, sales grew 2.6%, to US$117 million on  a U.S. dollar basis. When converted to yen, sales increased  23.7%, to ¥11.7 billion. In terms of patient days per month,  MyCAMINE gained a share of around 80% in the U.S.  market for injectable candin-type antifungal agents. In the  U.S., we obtained approval for an additional pediatric  indication in June 2013. In EMEA, sales steadily grew by 17.5% to  € 65 million,  which was a 47.3% increase, to ¥8.8 billion on a yen basis.  Distribution of MyCAMINE has expanded to cover 38  European countries. In Asia & Oceania, sales grew 44.6%, to ¥3.4 billion,  including healthy growth in China. Meanwhile, this product  was approved in Australia in May 2013, in Malaysia in  August 2013, and in Singapore in December 2013 and  sales launched in each of these countries.